A Phase 2 interventional study of E2020 and E2020 in Alzheimer's Type Dementia, sponsored by Eisai Inc.. Completed at 11 sites in Japan. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2014-08-08.
Sponsored by Eisai Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 60 studies testing donepezil in Alzheimer Disease — 2 open to participants now, 2 under way, 1 of them phase 3. Donepezil · Alzheimer Disease.
Among the 60 studies testing donepezil in Alzheimer Disease, this one is the 36th largest by enrollment of the 58 interventional ones that give a count, is one of 3 that started in 2011, is one of 4 in phase 2, and was the 32nd registered.
3,970 studies on the registry are indexed under Alzheimer Disease; 928 are open to participants now.
Browse Alzheimer Disease studies →2 of the 60 studies testing donepezil in Alzheimer Disease are open now, in 1 country. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 50+
Eisai Inc.
Ages 50–85
By country, each count listing its studies:
Donepezil: first FDA approval 1996 (ARICEPT). What it is approved for, and how studies give it, is on its page →
Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
60 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 3 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 45 is below the median of 70 across 3,021 interventional studies indexed under Alzheimer Disease.
Median enrollment 79 across the 58 interventional studies. Of the 56 that completed or were terminated, 21 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 60 have an industry lead sponsor. The 10 most frequent:
This study is registered under Eisai Inc., one of the names counted as Eisai Co., Ltd.. Under that name alone:
Eisai Inc. is the lead sponsor of 368 studies on the registry; 7 are open to participants now.
Of its 83 completed or terminated interventional studies of FDA-regulated products, 56 (67%) have results posted.
46 studies in Alzheimer Disease by Eisai Co., Ltd.: 7 open now, 12 under way, 2 of them phase 3. Of 33 finished, 11 (33%) have results posted.
Among the 46 studies in Alzheimer Disease by Eisai Co., Ltd., this one is the 22nd largest by enrollment of the 30 interventional ones that give a count, is one of 2 that started in 2011, is one of 5 in phase 2, and was the 17th registered.
Eisai Co., Ltd.’s Alzheimer Disease studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 60 studies testing donepezil in Alzheimer Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eisai Co., Ltd.’s 46 in Alzheimer Disease:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare 23 mg donepezil sustained release (SR) to the currently marketed formulation of 10 mg donepezil immediate release (IR) in patients with severe Alzheimer's disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: E2020
Drug: E2020
Patients will take study medication orally, once daily, for 2 weeks according to a double-dummy design in the double blind phase: 23 mg donepezil sustained release (SR) concurrently with placebo identical in appearance to the 10 mg donepezil immediate release (IR) formulation
10 mg donepezil immediate release (IR) concurrently with placebo identical in appearance to the 23 mg donepezil sustained release (SR) formulation. All patients who complete the double blind phase will take 23 mg donepezil sustained release (SR) orally, once daily, for 52 weeks in the Open-label Extension phase.
Maximum Observed Plasma Concentration (Cmax) of E2020 on Visits 2 and 3
Time frame: Visit 2 [Day1] and Visit 3 [Day 15]
Cmax of E2020 on Visits 2 and 3 According to Cytochrome P450 2D6 (CYP2D6) Phenotype Status
All subjects were identified as Extensive Metabolizer \[EM\] or Intermediate Metabolizer \[IM\] predicted from their CYP2D6 phenotypes. Ultra-rapid Metabolizer (UM) and Poor Metabolizer (PM) were not identified in any subject. Since the analysis population i
Time frame: Visit 2 [Day1] and Visit 3 [Day 15]
| Milestone | E2020 SR 23 mg | E2020 10 mg |
|---|---|---|
| Started | 22 | 23 |
| Completed | 19 | 23 |
| Not completed | 3 | 0 |
| Withdrew: Adverse event | 2 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Milestone | E2020 SR 23 mg | E2020 10 mg |
|---|---|---|
| Started | 19 | 23 |
| Completed | 12 | 14 |
| Not completed | 7 | 9 |
| Withdrew: Adverse event | 2 | 5 |
| Withdrew: Withdrawal by subject | 1 | 2 |
| Withdrew: Withdrawal of study drug 4 days in a row | 3 | 1 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Prohibited concomitant medications | 0 | 1 |
All subjects were identified as Extensive Metabolizer \[EM\] or Intermediate Metabolizer \[IM\] predicted from their CYP2D6 phenotypes. Ultra-rapid Metabolizer (UM) and Poor Metabolizer (PM) were not identified in any subject. Since the analysis population i
| ng/mL | E2020 SR 23 mg | E2020 10 mg (EM) |
|---|---|---|
| Visit 2 EM [IR: n=16, SR: n=17] | 117.999 ± 28.898 | 98.117 ± 32.323 |
| Visit 2 IM [IR: n=5, SR: n=4] | 161.363 ± 18.761 | 104.294 ± 23.962 |
| Visit 3 EM [IR: n=16, SR: n=15] | 116.771 ± 31.663 | 63.896 ± 20.662 |
| Visit 2 IM [IR: n=5, SR: n=3] | 182.953 ± 48.422 | 79.802 ± 24.984 |
| ng/mL | E2020 SR 23 mg | E2020 10 mg |
|---|---|---|
| Visit 2 | 126.503 ± 31.27 | 97.006 ± 32.934 |
| Visit 3 | 127.335 ± 40.654 | 66.081 ± 24 |
Collected over Up to 54 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| E2020 SR 23 mg (Double-blind) | — | 0/22 (0%) | 13/22 (59.1%) |
| E2020 10 mg (Double-blind) | — | 0/23 (0%) | 2/23 (8.7%) |
| E2020 SR 23 mg (Extension) | — | 0/19 (0%) | 9/19 (47.4%) |
| E2020 10 mg (Extension) | — | 1/23 (4.3%) | 16/23 (69.6%) |
| Event | E2020 SR 23 mg (Double-blind) | E2020 10 mg (Double-blind) | E2020 SR 23 mg (Extension) | E2020 10 mg (Extension) |
|---|---|---|---|---|
| AtaxiaNervous system disorders | 0/22 | 0/23 | 0/19 | 1/23 |
| Event | E2020 SR 23 mg (Double-blind) | E2020 10 mg (Double-blind) | E2020 SR 23 mg (Extension) | E2020 10 mg (Extension) |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 3/22 | 1/23 | 0/19 | 7/23 |
| VomitingGastrointestinal disorders | 4/22 | 1/23 | 0/19 | 7/23 |
| Decreased appetiteMetabolism and nutrition disorders | 6/22 | 0/23 | 3/19 | 4/23 |
| SomnolenceNervous system disorders | 2/22 | 0/23 | 1/19 | 4/23 |
| Weight decreasedInvestigations | 2/22 | 0/23 | 3/19 | 1/23 |
| DiarrhoeaGastrointestinal disorders | 3/22 | 1/23 | 2/19 | 0/23 |
| Electrocardiogram QT prolongedInvestigations | 2/22 | 0/23 | 1/19 | 0/23 |
| ConstipationGastrointestinal disorders | 0/22 | 0/23 | 0/19 | 2/23 |
| Eye DischargeEye disorders | 0/22 | 0/23 | 1/19 | 0/23 |
| EpulisGastrointestinal disorders | 0/22 | 0/23 | 1/19 | 0/23 |
| Age, Continuous(Years) | E2020 SR 23 mg | E2020 10 mg | Total |
|---|---|---|---|
| Mean | 79.3 ± 9.8 | 73.6 ± 10.8 | 76.4 ± 10.6 |
| Sex: Female, Male(Participants) | E2020 SR 23 mg | E2020 10 mg | Total |
|---|---|---|---|
| Female | 16 | 16 | 32 |
| Male | 6 | 7 | 13 |
| Hachinski Score(Scores on a Scale) | E2020 SR 23 mg | E2020 10 mg | Total |
|---|---|---|---|
| Mean | 1.1 ± 1.3 | 0.7 ± 1.1 | 0.9 ± 1.2 |
The record gives a start of Jan 2011, a primary completion of Apr 2012 and a completion of Apr 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2014, 2 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Donepezil